TCON TRACON Pharmaceuticals Inc.

0.58
0  -1%
Previous Close 0.59
Open 0.6
Price To Book 1.19
Market Cap 17,513,412
Shares 29,937,457
Volume 112,320
Short Ratio
Av. Daily Volume 242,574

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Enrolment to be terminated - April 12, 2019.
TRC105 + Opdivo
Non-small cell lung cancer (NSCLC)
Phase 2 data due 2H 2020.
TRC253
Prostate cancer
Phase 2 data due 1H 2020.
DE-122 and Lucentis - AVANTE
Wet age-related macular degeneration (Wet-AMD)
Phase 2 data December 21, 2018 did not meet primary endpoint.
TRC105 and Inlyta
Renal Cell Carcinoma (RCC) - cancer
Phase 2 data released February 9, 2017 - primary endpoint not met.
TRC105 and Avastin
Glioblastoma - cancer
Phase 2 primary endpoint not met - November 19, 2018.
TRC102 and Temodar
Glioblastoma - cancer
Phase 2 initiated October 2015. Data are due in 2020.
TRC102
Mesothelioma cancer
Phase 3 interim analysis April 12, 2019 noted trial to be terminated due to futility.
TRC105 (TAPPAS)
Angiosarcoma cancer
Phase 2 poster presented April 3, 2019 at AACR.
TRC102 and Temodar (temozolomide)
Colorectal cancer

Latest News

  1. TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer
  2. Is TRACON Pharmaceuticals, Inc.'s (NASDAQ:TCON) Balance Sheet A Threat To Its Future?
  3. TRACON Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
  4. Edited Transcript of TCON earnings conference call or presentation 14-May-19 8:30pm GMT
  5. Tracon: 1Q Earnings Snapshot
  6. TRACON Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
  7. TRACON Pharmaceuticals, Inc. to Host Earnings Call
  8. TRACON to Report First Quarter 2019 Company Highlights and Financial Results on May 14, 2019
  9. Bad news for Apple, Tracon slides, Boeing completes test flights
  10. TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee
  11. TRACON Pharmaceuticals Announces TRC105, TRC253 and TRC102 Data Presentations at Upcoming AACR Annual Meeting
  12. How Should Investors React To TRACON Pharmaceuticals, Inc.’s (NASDAQ:TCON) CEO Pay?
  13. Edited Transcript of TCON earnings conference call or presentation 28-Feb-19 9:30pm GMT
  14. TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
  15. TRACON to Report Fourth Quarter and Full Year 2018 Company Highlights and Financial Results on February 28, 2019
  16. TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma
  17. Analysis: Positioning to Benefit within PPL, Inseego, Scientific Games, Orgenesis, CUI Global, and TRACON Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results
  18. Stocks to Watch Before The Opening Bell on December 27, 2018